🚨Publication Alert🚨
Check out this research lead by our CTO and President of Bioanalysis & Biomarkers, Meina Liang.
In this publication, she and a team of experts developed a branched DNA approach for quantification of antisense oligonucleotides (ASOs) demonstrating that this dual technology has significantly higher sensitivity and lower interferences compared to other existing bioanalytical methods.
📃 Read the article here: https://hubs.la/Q01sVxdk0
Antisense oligonucleotides (ASOs), a fast-growing drug modality, are small synthetic nucleotides that bind to a specific sequence of a target gene or protein with the capacity to inhibit gene expression or impede protein function. Along with the development of more potent and stable ASOs, there is a need for highly sensitive pharmacokinetic methods for ASOs characterization and quantification.
The results reported by Dr. Meina Liang and colleagues show that the branched DNA approach has significantly higher sensitivity representing a major advance in ASOs quantification and pharmacokinetic characterization. This is critical in determining efficacious dose levels and dosing frequency in ASOs clinical studies.
